New Stock Issuance - New stock issuance for AiFenda (301575) is priced at 27.69 RMB, effective from September 1, 2025[1] - Fushun Special Steel (600399) is undergoing a tender offer from August 12 to September 10, 2025[1] - KaiPu Cloud (688228) has a recent announcement regarding its stock[1] Market Alerts - Significant abnormal fluctuations reported for Siquan New Materials (301489) on August 22, 2025[1] - New announcements for various stocks including Xinhua Jin (600735) and Jishi Media (601929) on August 30, 2025[1] - Multiple stocks including ST Guohua (000004) and ST Huayang (603825) have recent updates as of August 29, 2025[1] Trading Insights - The report includes links to detailed announcements for stocks experiencing significant market activity, such as ST Zhongji (000972) and ST Yilanzhong (300096)[1] - The document highlights the importance of monitoring stock performance and related announcements for investment decisions[1]

Core Viewpoint - *ST Huicheng has experienced a significant stock price increase, achieving a limit-up and marking three consecutive trading days of gains, with a total increase of 15.83% over the past three days [1] Company Summary - The stock of *ST Huicheng has reached a limit-up, indicating strong market interest and investor confidence [1] - The cumulative increase of 15.83% over three days suggests a positive trend in the company's stock performance [1]

Core Viewpoint - *ST Huicheng (002168) reported a significant increase in revenue and a reduction in net loss for the first half of 2025, indicating potential recovery despite ongoing challenges [1]. Financial Performance Summary - Total revenue for the first half of 2025 reached 180 million yuan, a year-on-year increase of 61.54% compared to 111 million yuan in 2024 [1]. - The net profit attributable to shareholders was -31.67 million yuan, improving by 54.36% from -69.39 million yuan in the previous year [1]. - The gross profit margin improved to 51.22%, a substantial increase of 267.85% from 13.93% in 2024 [1]. - The net profit margin also improved to -14.06%, up 77.82% from -63.38% in the previous year [1]. - Operating cash flow per share increased to 0.07 yuan, a significant rise of 201.36% from -0.06 yuan [1]. Changes in Financial Items - Cash and cash equivalents increased by 328.26% to 65.89 million yuan due to increased sales collections [3]. - Accounts receivable rose by 71.18% to 246 million yuan, attributed to the consolidation of Reen Pharmaceutical [3]. - Long-term borrowings increased by 56.9% due to new long-term loans taken during the reporting period [4]. - Contract liabilities surged by 405.52% as a result of receiving project prepayments [4]. Cost and Expense Analysis - Sales expenses increased by 436.73% due to the addition of the pharmaceutical segment [4]. - Management expenses decreased by 48.2% as the company implemented cost-cutting measures [4]. - Research and development expenses rose by 108.33%, reflecting investment in the new pharmaceutical business [4]. Cash Flow and Debt Situation - The net cash flow from operating activities increased by 201.36%, driven by improved sales collections [4]. - The net increase in cash and cash equivalents was up by 151.56%, also due to increased sales collections [4]. - The company’s debt situation shows a significant reliance on interest-bearing liabilities, with a debt-to-asset ratio of 40.18% [5].

本次公司申请撤销其他风险警示事项不涉及股票停牌，公司股票正常交易。 格隆汇8月29日丨*ST惠程(002168.SZ)公布，2025年8月28日，公司召开第八届董事会第十三次会议，审 议通过《关于申请撤销公司股票其他风险警示的议案》，同意公司向深圳证券交易所申请撤销公司股票 其他风险警示。 鉴于公司2024年度经审计的期末归母净资产为负数、扣除非经常性损益后的净利润为负数且扣除后的营 业收入低于3亿元，公司股票自2025年4月30日起被实施退市风险警示。如深圳证券交易所核准公司本次 撤销公司股票其他风险警示的申请，公司股票仍继续被实施退市风险警示，公司股票简称仍为"*ST惠 程"，公司股票交易的日涨跌幅限制仍为5%。 ...

Core Viewpoint - *ST Huicheng (002168.SZ) reported a significant increase in revenue for the first half of 2025, but still faced substantial net losses [1] Financial Performance - The company achieved an operating revenue of 180 million yuan, representing a year-on-year growth of 61.54% [1] - The net profit attributable to shareholders of the listed company was -31.67 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -27.44 million yuan [1] - The basic earnings per share were -0.0404 yuan [1]

Core Insights - *ST Huicheng reported a decrease in the number of shareholders to 32,887 as of June 30, 2025, down by 4,564 or 12.19% from March 31, 2025 [1][2] - The average number of shares held per shareholder increased from 20,900 to 23,800, with an average market value of 79,200 yuan [1][2] - The stock price of *ST Huicheng increased by 48.21% during the period from March 31, 2025, to June 30, 2025, despite the reduction in shareholder numbers [1][2] Company Performance - As of June 30, 2025, *ST Huicheng's shareholder count was below the industry average of 37,700 [1] - The average market value of shares held by shareholders in the electric grid equipment industry was 244,400 yuan, significantly higher than *ST Huicheng's average [1] - From March 31, 2025, to June 30, 2025, the net outflow of main funds was 71.77 million yuan, while retail investors contributed a net inflow of 54.69 million yuan [2] Historical Comparison - The number of shareholders decreased from 40,161 on December 31, 2024, to 32,887 on June 30, 2025, reflecting a significant decline of 24.72% over the period [2] - The stock experienced a price drop of 19.13% from December 31, 2024, to March 31, 2025, before rebounding with a 48.21% increase in the subsequent quarter [2] - The average market value of shares held by shareholders has shown a steady increase from 41,000 yuan in September 2024 to 79,200 yuan in June 2025 [2]

Core Viewpoint - The company reported a significant increase in revenue for the first half of 2025, but still faced a net loss, indicating ongoing financial challenges despite improved operational performance [1][2]. Financial Performance - The company's operating revenue for the reporting period reached ¥179,792,680.55, representing a 61.54% increase compared to ¥111,298,587.00 in the same period last year [1]. - The net profit attributable to shareholders was a loss of ¥31,666,573.45, which is an improvement of 54.36% from a loss of ¥69,385,458.73 in the previous year [1]. - The net profit after deducting non-recurring gains and losses was a loss of ¥27,444,740.03, showing a 59.37% improvement from a loss of ¥67,542,511.49 [1]. - The net cash flow from operating activities was ¥51,188,378.54, a significant increase of 201.36% compared to a negative cash flow of ¥50,502,770.43 in the previous year [1]. Balance Sheet - Total assets at the end of the reporting period were ¥952,069,286.07, reflecting a 20.33% increase from ¥791,218,924.57 at the end of the previous year [2]. - The net assets attributable to shareholders were negative at ¥-95,785,444.50, a decline of 74.72% from ¥-54,823,505.99 at the end of the previous year [2]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 32,887 [2]. - The largest shareholder, Chongqing Green Development Urban Construction Co., Ltd., holds 12.15% of the shares, amounting to 95,303,911 shares [2]. - Other significant shareholders include Zhongchi Huicheng Enterprise Management Co., Ltd. with 5.90% and Hu Zuping with 3.95% [2]. Important Matters - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [1][4]. - There were no changes in the controlling shareholder or actual controller during the reporting period [4].

Core Viewpoint - Chongqing Hifuture Information Technology Co., Ltd. reported a significant increase in revenue and a reduction in net loss for the first half of 2025, driven by the expansion of its pharmaceutical segment and improvements in operational efficiency [2][3]. Financial Performance - The company's operating revenue for the reporting period reached approximately 179.79 million yuan, a 61.54% increase compared to 111.30 million yuan in the same period last year [2][6]. - The net profit attributable to shareholders was a loss of approximately 31.67 million yuan, which is a 54.36% improvement from a loss of 69.39 million yuan in the previous year [2][3]. - The net cash flow from operating activities was approximately 51.19 million yuan, a significant turnaround from a negative cash flow of 50.50 million yuan in the previous year, marking a 201.36% increase [2][3]. Business Segments - The company operates in four main business segments: power distribution equipment, electric vehicle charging stations, photovoltaic and wind power EPC projects, and biopharmaceuticals [3][5]. - The pharmaceutical segment contributed significantly to revenue, generating approximately 103.23 million yuan, accounting for 57.41% of total revenue, which was a new addition to the company's portfolio [6]. - The electric vehicle charging station segment, through its subsidiary, provided integrated solutions for charging systems, with products designed for efficiency and safety [3][5]. Cost Management - The company's operating costs decreased by 8.46% to approximately 87.70 million yuan, reflecting effective cost control measures [5][6]. - Sales expenses surged by 436.73% to approximately 56.10 million yuan, primarily due to the expansion of the pharmaceutical business [5][6]. - Management expenses decreased by 48.20% to approximately 26.69 million yuan, indicating improved operational efficiency [5][6]. Asset and Liability Analysis - Total assets increased by 20.33% to approximately 952.07 million yuan compared to the previous year [2][8]. - The company's net assets attributable to shareholders were negative at approximately -95.79 million yuan, a decline of 74.72% from the previous year [2][8]. - The company reported an increase in accounts receivable, which reached approximately 245.67 million yuan, accounting for 25.80% of total assets [8][9]. Strategic Advantages - The company has established a strong brand presence in the power distribution equipment sector, leveraging over 20 years of industry experience [3][5]. - Continuous investment in research and development, particularly in the pharmaceutical sector, has enhanced the company's innovation capabilities [5][6]. - The strategic collaboration with local government resources is expected to create synergies that will support the company's growth trajectory [5][6].

证券代码：002168 证券简称：*ST惠程 公告编号：2025－066 本公司及董事会全体成员保证公告内容的真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 重庆惠程信息科技股份有限公司（以下简称"公司"）第八届董事会第十三 次会议于2025年8月28日以现场及通讯表决方式在公司会议室召开，本次会议通 知已于2025年8月18日以电子邮件和即时通讯工具的方式送达给全体董事、监事、 高级管理人员。本次会议应出席董事5人，实际出席会议的董事5人。本次会议的 召开程序符合《中华人民共和国公司法》（以下简称"《公司法》"）及《公司 章程》的规定，合法有效。本次会议由董事长艾远鹏先生主持，经全体董事认真 审议后，采用记名投票表决的方式审议通过了如下议案： 一、会议以5票同意、0票弃权、0票反对，审议通过《关于＜惠程科技2025 年半年度报告＞及其摘要的议案》。 本报告已经公司董事会审计委员会审议通过。 具体内容详见公司于2025年8月30日在巨潮资讯网（www.cninfo.com.cn）披 露的《2025年半年度报告摘要》（公告编号：2025-068）、《2025年半年度报告》。 二、会议以5票同意、0票 ...

Core Viewpoint - The company is applying to revoke the other risk warning on its stock while continuing to be subject to delisting risk warning due to negative net assets and insufficient operating revenue [1][4]. Group 1: Company’s Current Situation - The company’s net profit is negative, and its operating revenue after deductions is below 300 million [1][4]. - The stock has been under other risk warnings since September 19, 2024, following an administrative penalty from the China Securities Regulatory Commission [2][3]. Group 2: Application for Revocation of Risk Warning - The company has rectified the issues related to the administrative penalty and has restated its financial reports accordingly [2][3]. - The company has completed the necessary conditions for applying for the revocation of the other risk warning, including the passage of twelve months since the administrative penalty [3]. Group 3: Future Risks and Considerations - If the company’s financial situation does not improve, it may face termination of its stock listing if it continues to meet the criteria for delisting [4][5]. - The company is under a pre-restructuring application due to its inability to repay debts, which adds uncertainty to its future operations [5].